TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2671218

Group type: EXPERIMENTAL
Intervention: Topical Bupivacaine 0.5 per cent solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study: 776539

Group type: EXPERIMENTAL
Intervention: tolmetin 1200 mg per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: tolmetin 1400 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: indomethacin 150 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 31689951

Group type: EXPERIMENTAL
Intervention: L-isoleucine (0.3 g/kg·LBM-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-leucine (0.3 g/kg·LBM-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Equal (1:1 g) of L-leucine + L-isoleucine (0.3 g/kg·LBM-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (3.5 g inert stevia)
Number of subjects: 12
Study: 27862713

Group type: EXPERIMENTAL
Intervention: Alcohol-promoting advertisements
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Alcohol-warning advertisements
Number of subjects: 204

Group type: COMPARATOR
Intervention: Non-alcohol advertisements
Number of subjects: 204
Study: 26041325

Group type: EXPERIMENTAL
Intervention: Emergency cervical cerclage (ECC) combined with progesterone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 100
Study: 24235245

Group type: EXPERIMENTAL
Intervention: 15% propolis solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no propolis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 days storage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14 days storage
Number of subjects: 0
Study: 21756795

Group type: EXPERIMENTAL
Intervention: Fibrin glue enwrapping cisplatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisplatin (control)
Number of subjects: 20
Study: 19567515

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) + acipimox
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: acipimox
Number of subjects: 7
Study: 16885888

Group type: EXPERIMENTAL
Intervention: Supranettes pads
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical antiallergic treatment (membrane stabilizer or antihistamine)
Number of subjects: 20
Study: 15491434

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus plus salicylic acid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo plus salicylic acid
Number of subjects: 24
Study: 11195308

Group type: EXPERIMENTAL
Intervention: Canonical patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex patterns broken down into small canonical patterns
Number of subjects: 0
Study: 9760291

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (specific type not mentioned)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Clinical and brain imaging characteristics
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 268
Study: 7826794

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 23
Study: 2898227

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular (ICV) cholinergic drug infusion (bethanechol chloride)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 29102231

Group type: EXPERIMENTAL
Intervention: Musician's earplugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No earplugs
Number of subjects: 0
Study: 29428819

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (CBM-HS and Psychoeducation)
Number of subjects: 32
Study: 27426441

Group type: EXPERIMENTAL
Intervention: Fractionated Er:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fully ablative Er:YAG laser
Number of subjects: 20
Study: 24035142

Group type: EXPERIMENTAL
Intervention: Intervener-delivered brief intervention (IBI)
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (CBI)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 781
Study: 22512894

Group type: EXPERIMENTAL
Intervention: RTG/EZG 600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTG/EZG 900 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTG/EZG 1200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19171853

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1002
Study: 17991911

Group type: EXPERIMENTAL
Intervention: Vigil (monitoring system intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched SCU without Vigil)
Number of subjects: 0
Study: 15969668

Group type: EXPERIMENTAL
Intervention: Low-dose peanut challenge
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11911553

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily
Number of subjects: 372

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 372
Study: 10546561

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) at 30 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) at 50 mg/kg
Number of subjects: 35
Study: 7768494

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 134
Study: 2283646

Group type: EXPERIMENTAL
Intervention: nifedipine retard 10 mg twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: atenolol 50 mg once daily
Number of subjects: 41
Study: 371396

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no TMP/SMZ)
Number of subjects: 111
Study: 6801218

Group type: EXPERIMENTAL
Intervention: Intracranial pressure monitoring and aggressive treatment (including mannitol therapy and drainage of cerebrospinal fluid)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Previous treatment protocol (standardized protocol without aggressive ICP treatment)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: ICP greater than or equal to 25 mm Hg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: ICP monitoring with aggressive treatment
Number of subjects: 127
Study: 30744053

Group type: EXPERIMENTAL
Intervention: Healthy learning. Together. tool implemented by regular teachers in the intervention group (IG)
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1144
Study: 27499178

Group type: EXPERIMENTAL
Intervention: Titanium‐nitride‐oxide‐coated bioactive stents (BAS)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study: 27166670

Group type: EXPERIMENTAL
Intervention: Annual prostate‐specific antigen (PSA) screening for 6 years and digital rectal examination for 4 years
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Annual prostate‐specific antigen (PSA) screening
Number of subjects: 151
Study: 23775532

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal patch (TEP) hernioplasty
Number of subjects: 154

Group type: COMPARATOR
Intervention: Open tension‐free plug and patch (PP) technique
Number of subjects: 154
Study: 21745755

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19020533

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (MgCl(2)) 2.5 g (equivalent to 450 mg of elemental magnesium) for 4 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 17894706

Group type: EXPERIMENTAL
Intervention: Continuous cyclosporine (CyA) therapy at individualized effective doses
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intermittent cyclosporine (CyA) therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both treatment schedules
Number of subjects: 51
Study: 15250006

Group type: EXPERIMENTAL
Intervention: A‐V Impulse System (mechanical thrombembolic prophylaxis)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Low dose heparin (control group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 104
Study: 12176767

Group type: EXPERIMENTAL
Intervention: Trained group (29 persons) - received training on earplug insertion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Untrained group (25 persons) - acted as controls
Number of subjects: 54
Study: 10521819

Group type: EXPERIMENTAL
Intervention: Fetal cells identified using double-density gradient and MACS methods, followed by FISH technique.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fetal sex determination using identified fetal cells.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Confirmation of aneuploidies found in previous prenatal diagnosis.
Number of subjects: 66
Study: 7677459

Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion for 7 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control period (enteral feeding alone)
Number of subjects: 9
Study: 2205609

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture-like transcutaneous electrical nerve stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 11
Study: 6994791

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined metoclopramide and atropine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study: 31132908

Group type: EXPERIMENTAL
Intervention: Tablet and pen version
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pen and paper version
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tablet and finger version
Number of subjects: 30
Study: 27493198

Group type: EXPERIMENTAL
Intervention: Combination of fexofenadine and ranitidine (blockade)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 24
Study: 26187277

Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) adjunctive treatment for fractures, including Shu-jing-huo-xue-tang and Rhizoma Drynariae (Gu-sui-bu) as common prescriptions.
Number of subjects: 115327

Group type: COMPARATOR
Intervention: Non-TCM treatment for fractures (control group).
Number of subjects: 115327
Study: 22888821

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 588
Study: 20537624

Group type: EXPERIMENTAL
Intervention: Crinone
Number of subjects: 365

Group type: COMPARATOR
Intervention: Intramuscular progesterone (IMP)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 365
Study: 19591990

Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration initiated when the lead follicle reaches 14 mm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (GnRH antagonist administration not specified)
Number of subjects: 0
Study: 17224445

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 23
Study: 15482599

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 0
Study: 12014386

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) 0.2 mg/kg at 12 h intervals
Number of subjects: 232

Group type: COMPARATOR
Intervention: Ibuprofen (IBU) first dose 10 mg/kg followed by two doses of 5 mg/kg at 24 h intervals
Number of subjects: 232
Study: 10439371

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg i.v. 10 min before chemotherapy)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg i.v. 10 min before chemotherapy) + Alprazolam (1 mg per os 1 hour before chemotherapy, 0.5 mg at H+6 for C1; 0.75 or 1.5 mg at H-48, H-24, H-1 for C2 and C3, 0.5 mg at H+6)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Granisetron plus Alprazolam
Number of subjects: 225
Study: 7766738

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 50 micrograms of octreotide
Number of subjects: 9
Study: 2277579

Group type: EXPERIMENTAL
Intervention: Injection of 3 mL normal saline into the P6 acupuncture point after anesthesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard fentanyl-valium-thiopentone anesthesia alone
Number of subjects: 64
Study: 7470769

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg, 50 mg, 100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desipramine (25 mg, 50 mg, 100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amitriptyline and Desipramine
Number of subjects: 8
Study: 29374357

Group type: EXPERIMENTAL
Intervention: Stigmatizing language note
Number of subjects: 413

Group type: COMPARATOR
Intervention: Neutral language note
Number of subjects: 413
Study: 27379603

Group type: EXPERIMENTAL
Intervention: Interpersonal growth groups led by experienced psychologists for 9 weeks using Yalom and Leszcz's interpersonal process model.
Number of subjects: 325
Study: 24122296

Group type: EXPERIMENTAL
Intervention: Resistance and aerobic exercise intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 22618963

Group type: EXPERIMENTAL
Intervention: Let Us Protect Our Future intervention
Number of subjects: 0
Study: 20375263

Group type: EXPERIMENTAL
Intervention: Cranberry juice (480 mL; 54% juice; 835 mg total polyphenols; 94.47 mg anthocyanins)
Number of subjects: 15
Study: 18522171

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy using teniposide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 15781835

Group type: EXPERIMENTAL
Intervention: 1,000 mg of levetiracetam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12643118

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aggressive medical therapy
Number of subjects: 0
Study: 11034868

Group type: EXPERIMENTAL
Intervention: Side Effect and Life Satisfaction (SEALS) inventory
Number of subjects: 307

Group type: COMPARATOR
Intervention: Profile of Mood States (POMS)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression (HAD) scale
Number of subjects: 307

Group type: COMPARATOR
Intervention: Medical Outcomes Study‐Cognitive Functioning (MOS‐COG) scale
Number of subjects: 307
Study: 9346622

Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime and flucloxacillin plus oral and enteral decontamination with colistin, tobramycin, and amphotericin B (group 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Enteral amphotericin B alone (group 2)
Number of subjects: 108
Study: 1869454

Group type: EXPERIMENTAL
Intervention: Hyperfractionated RT (70.4 Gy in 64 fractions of 1.1 Gy given twice a day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional RT (66 Gy in 33 fractions of 2 Gy each)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Hyperfractionated RT
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional RT
Number of subjects: 112
Study: 6415595

Group type: EXPERIMENTAL
Intervention: Biolite (carbon‐coated) ventilation tubes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional silicone tube
Number of subjects: 44
Study: 31338732

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 22
Study: 29408562

Group type: EXPERIMENTAL
Intervention: High-intensity lifestyle intervention delivered by health coaches; 16 in-person sessions and 6 telephone sessions in the first 6 months, followed by at least monthly sessions for 18 months.
Number of subjects: 803

Group type: COMPARATOR
Intervention: Usual care provided by primary care practitioners with information on weight management and reimbursement for obesity treatment.
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: High-intensity lifestyle intervention
Number of subjects: 803
Study: 27080034

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily on-demand
Number of subjects: 598

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg daily continuously
Number of subjects: 598
Study: 25265102

Group type: EXPERIMENTAL
Intervention: Precall
Number of subjects: 29
Study: 23159552

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting or endarterectomy
Number of subjects: 2272
Study: 21260942

Group type: EXPERIMENTAL
Intervention: Entropy monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard monitoring)
Number of subjects: 50
Study: 18058456

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Lisinopril 10 mg
Number of subjects: 355
Study: 16102231

Group type: EXPERIMENTAL
Intervention: Perceptual go/no-go task based on spatial, temporal, or object stimulus features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual go/no-go task
Number of subjects: 0
Study: 12100802

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia
Number of subjects: 220

Group type: COMPARATOR
Intervention: Patient-controlled intravenous meperidine
Number of subjects: 220
Study: 10626032

Group type: EXPERIMENTAL
Intervention: 44 mg/24 hour nicotine patch for 4 weeks
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 22 mg/24 hour nicotine patch for 6 weeks
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (minimal, brief individual counseling, group therapy)
Number of subjects: 382
Study: 7476297

Group type: EXPERIMENTAL
Intervention: 1.0 g ethanol/kg body weight
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.5 g ethanol/kg body weight
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (0 g ethanol/kg body weight)
Number of subjects: 9
Study: 1493666

Group type: EXPERIMENTAL
Intervention: 12,000 U calcium heparin s.c. every 24 h (group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional treatment (group 1)
Number of subjects: 80
Study: 2862370

Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg single oral dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC, daily for eight days, total dose 1.3 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 30
Study: 29189517

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27033026

Group type: EXPERIMENTAL
Intervention: omega‐3 (4 g/day) and vitamin E (400 IU/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: omega‐3 (4 g/day) and vitamin E placebo (OP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: omega‐3 and vitamin E placebos (PP)
Number of subjects: 60
Study: 25471216

Group type: EXPERIMENTAL
Intervention: DHA (420 mg) + EPA (80 mg) supplementation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Iron (50 mg) supplementation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Iron (50 mg) + DHA (420 mg) + EPA (80 mg) supplementation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 23225089

Group type: EXPERIMENTAL
Intervention: 2% polyvinylpyrrolidone and 0.1% clobetasone butyrate, 1 drop BID
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% polyvinylpyrrolidone eyedrops and placebo
Number of subjects: 40
Study: 21633832

Group type: EXPERIMENTAL
Intervention: Serum sTREM-1 below the limit of detection
Number of subjects: 96

Group type: COMPARATOR
Intervention: Serum sTREM-1 above the limit of detection
Number of subjects: 96
Study: 19281081

Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (carbocisteine)
Number of subjects: 0
Study: 16411052

Group type: EXPERIMENTAL
Intervention: GP arm (intervention)
Number of subjects: 3657

Group type: COMPARATOR
Intervention: Hospital arm (control)
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: GPs with more than 25 patients visited/day
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: GPs incorrectly recommending screening of colorectal cancer
Number of subjects: 3657
Study: 12496140

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion (125 mg/kg/h for 15 min, then 25 mg/kg/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 10857934

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 34

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 34
Study: 9506873

Group type: EXPERIMENTAL
Intervention: Multimodal cognitive behavioral treatment (MMCBT) for 4 weeks
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group (ordinary treatment through general practitioners)
Number of subjects: 469
Study: 7931189

Group type: EXPERIMENTAL
Intervention: IFN-alpha therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HBV DNA detection in PBMC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HBV DNA in different cell types
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Presence of multimers of free HBV DNA
Number of subjects: 50
Study: 3290578

Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist [D‐Trp6]LHRH ethylamide for an average of 26 months (3‐59 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist [D‐Trp6]LHRH ethylamide
Number of subjects: 199
Study: 31734452

Group type: EXPERIMENTAL
Intervention: Modified global alignment and proportion scoring with body mass index and bone mineral density (GAPB)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Global alignment and proportion (GAP) score
Number of subjects: 203

Group type: COMPARATOR
Intervention: Scoliosis Research Society (SRS)‐Schwab classification
Number of subjects: 203

Group type: COMPARATOR
Intervention: Age‐adjusted alignment goals
Number of subjects: 203